- In late June 2026, Abbott Laboratories was added to the Russell 1000 Dynamic Index shortly after being removed from the Russell Top 50 Index, while the U.S. Department of Justice closed its criminal probe into the company’s Michigan baby formula plant in favor of pursuing civil penalties.
- At the same time, fresh upbeat analyst coverage and a series of director stock-equivalent grants underscored improved sentiment and ongoing alignment between Abbott’s leadership and shareholders following resolution of a key regulatory overhang.
- We’ll now examine how the closure of the criminal probe, shifting to civil penalties, influences Abbott’s existing investment narrative and risks.
We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Abbott Laboratories Investment Narrative Recap
To own Abbott, you need to believe its diversified healthcare portfolio and product pipeline can offset ongoing margin pressure and legal and regulatory costs. The shift from a criminal probe to civil penalties around the Michigan formula plant appears material mainly because it clarifies legal exposure and removes a major overhang, while near term catalysts still center on new device launches and diagnostics innovation; key risks remain pricing pressure in diagnostics and potential litigation costs.
The most relevant recent development is the Department of Justice’s decision to pursue civil penalties under the False Claims Act related to the formula plant. This directly ties into Abbott’s existing litigation and regulatory risk, giving investors more visibility on one of the largest outstanding legal issues even as other catalysts, such as continued roll out of diabetes and cardiovascular technologies, remain central to the thesis.
However, investors should also recognize that legal and regulatory exposures could still pressure margins and cash flows if...
Read the full narrative on Abbott Laboratories (it's free!)
Abbott Laboratories’ narrative projects $59.6 billion revenue and $9.5 billion earnings by 2029. This requires 9.7% yearly revenue growth and about a $3.2 billion earnings increase from $6.3 billion today.
Uncover how Abbott Laboratories' forecasts yield a $116.54 fair value, a 22% upside to its current price.
Exploring Other Perspectives
Six members of the Simply Wall St Community currently see Abbott’s fair value between US$116.54 and US$147.12, highlighting a wide range of expectations. Against this backdrop, ongoing pricing pressure and regulatory risks in diagnostics could influence how those differing views translate into future performance, so it is worth weighing several viewpoints before forming your own.
Explore 6 other fair value estimates on Abbott Laboratories - why the stock might be worth just $116.54!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Abbott Laboratories research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.
Looking For Alternative Opportunities?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com